<DOC>
	<DOCNO>NCT01040195</DOCNO>
	<brief_summary>Till drug conclusively show affect natural course inflammatory back ache seronegative spondylarthropathies . Non-steroidal anti-inflammatory drug ( NSAIDS ) main stay treatment disease long . Despite provide good pain relief , largely ineffective alter natural course disease . However , often , spite therapy , pain discomfort continue patient recurrent exacerbation . Other drug try patient . The DMARDS ( Disease Modifying Anti Rheumatic Drugs ) group drug come prominence follow remarkable efficacy management Rheumatoid Arthritis , another chronic inflammatory autoimmune arthritis . The major drug come group Methotrexate , Sulfasalazine , Hydroxychloroquine Leflunomide . Of drug , well study drug Spondylarthropathy Sulfasalazine . Trials show variable result response spondyloarthropathy sulfasalazine . The major DMARD try methotrexate . Though large well control trial lack , available data efficacy spondyloarthropathy favorable . Leflunomide , major DMARD also fare poorly control trial ankylose spondylitis . There present inadequate data regard efficacy Hydroxychloroquine . The discovery anti TNF-α major breakthrough management ankylose spondylitis ( AS ) Spondyloarthropathies ( SpA ) . These drug , besides provide symptomatic improvement , also produce improvement index disease activity Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) Assessment Spondylo-Arthritis International Society ( ASAS ) . Besides , enormous cost , incur rate Rs 700,000/- per annum , put reach majority affect population . Add increase risk tuberculosis fungal infection , major problem India . In background severe press need alternate safe effective drug management disease . It combination DMARD therapy assume importance potential safe cheap alternative . We aim assess efficacy combination DMARD therapy patient early inflammatory chronic backache patient sero negative spondyloarthropathies .</brief_summary>
	<brief_title>Combination Disease-Modifying Antirheumatic Drugs ( DMARDs ) Versus Sulfasalazine Inflammatory Back Pain</brief_title>
	<detailed_description>Spondyloarthropathies SpA</detailed_description>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Patients fulfil criterion diagnosis Ankylosing Spondylitis ( Modified New York Criteria ) undifferentiated spondyloarthropathy ( UspA ) ( Amor criterion ) within 8 year disease onset : Inflammatory back Pain 6 month BASDAI ≥4 EMS ≥45 minute Have fail maximum dose least one NSAID 6 week . Patients renal disease patient hepatic disease Patients severe uncorrected anemia ( Hb &lt; 7gm ) Patients previously receive full dose sulfasalazine and/or methotrexate inadequate relief Pregnant lactating female Malignancy active infection Patient require afford biologicals Patients receive steroid past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>ankylose spondylitis</keyword>
	<keyword>undifferentiated spondyloarthropathy</keyword>
	<keyword>spondyloarthropathy</keyword>
	<keyword>inflammatory back pain</keyword>
	<keyword>methotrexate</keyword>
	<keyword>sulfasalazine</keyword>
	<keyword>hydroxychloroquine</keyword>
</DOC>